Compare FRSX & TIVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSX | TIVC |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.6M |
| IPO Year | 2016 | 2021 |
| Metric | FRSX | TIVC |
|---|---|---|
| Price | $2.00 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.1K | ★ 89.7K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.31 | $0.75 |
| 52 Week High | $3.00 | $5.60 |
| Indicator | FRSX | TIVC |
|---|---|---|
| Relative Strength Index (RSI) | 38.24 | 69.31 |
| Support Level | $0.83 | $0.79 |
| Resistance Level | $2.33 | $2.70 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 8.21 | 100.00 |
Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.